Elekta Unity MR-Linac presented in 72 abstracts at the European Congress of Radiation Oncology
MADRID, August 31, 2021 / PRNewswire / – Elekta (EKTA-B.ST) today announced the presentation of 72 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted in 14 leading cancer centers around the world, reflecting the wide global adoption of the system. The summaries were reported to European society for radiotherapy and Oncology (ESTRO) which took place from August 27 to 31 in Madrid, Spain.
âThe Elekta Unity data presented at ESTRO includes an increasing number of abstracts reporting clinical data in multiple anatomical sites, which is a direct result of increased clinical implementation and maturation,â said Kevin brown, distinguished scientist at Elekta. “We are particularly excited about eight reports regarding MRI-based biomarkers that can predict response to treatment, which can help optimize patient selection and ensure patients receive personalized treatment based on their tumor biology. unique. These reports demonstrate the ease with which this biomarker data can be acquired during a Unity treatment session, reducing barriers to impactful research. This facility will also be essential for a possible cost-effective implementation of the research results. There are also several summaries that use data from the MOMENTUM study, which is designed to create a strong body of real-world clinical data and information and facilitate understanding of how Elekta Unity can be deployed in clinical practice to improve patient outcomes. ”
Mr Brown highlighted several summaries that illustrate the innovative approaches that members of the MR-Linac consortium are pursuing to optimize the clinical use of Elekta Unity in real-world settings:
To maintain and increase the use of advanced MRgRT technology, the traditional roles and responsibilities of radiographers, clinicians and physicists may need to evolve. This summary describes an effort to provide an in-depth understanding and subsequent impact of the roles required to provide MRgRT using focus group interviews. Thirty participants took part (radiographers: n = 18, physicists: n = 9 and clinicians: n = 3), and the consensus within the group was to move towards a process led by a radiologist with training given preferably mixed, both before and during treatments. The authors conclude that roles need to be created with sufficient support and strong governance to allow assessment of effectiveness, impact, continued sustainability and responsiveness. A training framework created in collaboration with all stakeholders and relevant professions would ensure consistency of skills and knowledge.
MRI images are less geometrically accurate compared to CT images, which may impact the delivery of the radiation dose in MRgRT. This summary describes the first results of a Danish national network for the quality assurance (QA) of MRI images used in radiotherapy in Denmark. A general MRI sequence was used to test the geometric accuracy of MRI scans (n ââ= 8) and MRI-linacs (n = 2) in seven of the eight Danish radiotherapy centers and one radiology department. With the exception of an MRI scanner, the results were less than 0.43 mm in a spherical volume 200 mm in diameter and less than 1.2 mm for a spherical volume of 350 mm in diameter (DSV). No dependence on the strength of the magnetic field was observed. These results demonstrate both the ability to deliver precision MR-led radiotherapy workflow and the value of quality assurance systems in optimizing MRgRT.
As the world’s first high-field MRI-guided radiotherapy system, Elekta Unity enables novel therapeutic approaches for a wide range of cancers, including prostate cancer. To ensure that the promise of this technology is fully realized, the MR-linac consortium launched the MOMENTUM study, which is designed to build a solid body of clinical data and concrete information regarding the implementation and use of Elekta Unity. This summary describes the first data from the MOMENTUM study and includes the short-term results (three and six months of follow-up [FU]) for 156 prostate cancer patients treated with ultrahypofractional radiotherapy (5 x 7.25 Gray). No grade â¥3 genitourinary or gastrointestinal toxicity has been reported, and no significant deterioration in patient-reported outcome scores has been observed. The percentage of men who reported no difficulty getting or maintaining an erection remained constant throughout FU (44.4% at baseline, 40.0% at 3 months FU, and 42.9% at 6 months FU). These results confirm the safety and efficacy of ultrahypofractionated radiotherapy administered with Elekta Unity for the treatment of prostate cancer.
For imaging biomarkers acquired on MR-Linacs to be useful, they must be accurate, reproducible on individual patients, and reproducible on different MR-Linacs. The aim of this study was to determine the repeatability of the apparent values ââof the diffusion coefficient derived from diffusion-weighted MRI in patients with head and neck cancer acquired on Elekta Unity. When analyzed at the volume of interest level, the intra-subject coefficient of variation ranged from 3.3% in the parotid glands to 8.3% in the GTV. These are promising results and support further development towards quantitative MRI for online adaptive RT.
To learn more about Elekta Unity, visit elekta.com/Unity.
Elekta Unity has CE mark and 510 (k) clearance, but is not available in all markets.
# # #
For more information, please contact:
Mattias Thorsson, Vice-President, Corporate Communications
Tel: +46 70 865 8012, e-mail: [emailÂ protected]
Time zone: CET: Central European Time
Canzeri Crow, head of global public relations
Tel: +1 770 670 2524, e-mail: [emailÂ protected]
Time Zone: ET: Eastern Time
For nearly five decades, Elekta has been a leader in precision radiological medicine. Our more than 4,400 employees around the world are committed to ensuring that everyone living with cancer around the world has access to and benefits from more accurate and personalized radiation treatment. Based at Stockholm, Sweden, Elekta is listed on the NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: